Ionis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Ionis Pharmaceuticals (IONS) PT Raised to $67 at BMO Capital; Buy on Weakness
July 25, 2017 1:51 PM EDTBMO Capital raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $67.00 (from $62.00) while maintaining a Outperform rating.
Analyst Do Kim recommends buying on weakness following Biogen comments on Spinraza growth to slow in 2H17.
"We believe Spinraza has... More
Buy Ionis Pharmaceuticals (IONS) on Growth Concerns Weakness - Needham & Company
July 25, 2017 12:05 PM EDTNeedham & Company analyst Chad Messer is telling clients to buy Ionis Pharmaceuticals (NASDAQ: IONS) on weakness as growth concerns overlook the longer-term opportunity.
Messer notes partner Biogen reported $203M in 2Q SPRINRAZA sales, a dramatic increase from $47M in 1Q... More
